BRL-303

BRL-303 is an allogeneic universal chimeric antigen receptor T cell (UCAR-T) therapy developed by BRL Medicine. It is designed to target CD19, a protein expressed on the surface of B cells, and acts as a CD19 inhibitor. The therapy represents a next-generation approach in CAR-T technology, utilizing gene editing to create universal donor T cells that can be administered to multiple patients without the need for individualized manufacturing. Its primary indication is for autoimmune diseases, where it aims to modulate aberrant immune responses by depleting pathogenic B cells. Research on BRL-303 has been recognized as a significant clinical breakthrough in China and has received positive attention from leading experts in the field of cell therapy[1][2][3][7].